Survey on the Pharmaceutical Strategy - Timely patient access to affordable medicines

Fields marked with * are mandatory.

Introduction

The EU strives to be a frontrunner in ensuring universal health coverage. In addition, it is a global leader in healthcare research and development and a major trading partner in pharmaceuticals and medical technologies. People across the EU expect to benefit from equal access to safe, state-of-the-art and affordable new and established therapies. Medicines play an important role in this regard, as they offer therapeutic options for diagnosis, treatment and prevention of diseases.

The unprecedented coronavirus pandemic (COVID-19) clearly demonstrates the need to modernise the way the EU ensures that its citizens get the medicines they need. Although this has been thrown into sharp relief by the coronavirus pandemic, it is not a new problem: even prior to the pandemic we witnessed shortages of essential medicines, such as cancer treatments, vaccines and antimicrobials. This calls for a thorough examination of how the supply chain - from the importing of active ingredients, raw materials, and medicines from third countries to internal EU production and distribution – can be made more secure and reliable.

Securing the supply of medicines is not only about existing therapies. There is also a need to ensure that the European pharmaceutical industry remains an innovator and world leader. Innovative technologies such as artificial intelligence as well as data collected from clinical experience (“real world data”) have the potential to transform therapeutic approaches and the way medicines are developed, produced, authorised and placed on the market and used. Innovation needs to be focused on areas of most need.

At the same time, more must be done to ensure that innovative and promising therapies reach all patients who need them: at present, this is not the case, with patients in smaller markets being particularly affected. Health systems, which are also seeking to ensure their financial and fiscal sustainability, need new therapies that are clinically better than existing alternatives as well as cost effective.

Finally, we are more aware than ever of the need to reduce the environmental footprint of medicines.

All these challenges will be addressed in the forthcoming EU Pharmaceutical Strategy, which should cover the whole life-cycle of pharmaceutical products from scientific discovery to authorisation and patient access.

More information on the context of the initiative, on the challenges identified so far and on the objectives can be found in the roadmap (https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12421-Pharmaceutical-Strategy-Timely-patient-access-to-affordable-medicines). Whether you are a concerned citizen or a professional in the area of medicines we would like you to let us know if you share our
objectives, what actions we should focus on and whether there are any additional aspects that we should
cover.

After some introductory questions about yourself, the questionnaire continues with questions on the
Pharmaceutical strategy.

When replying, please keep in mind that the questions in this survey were developed to address the long-
standing issues identified in the EU pharmaceuticals system. These may be related to the problems arising
from the coronavirus pandemic but are broader than that. The end of the survey includes dedicated
questions on coronavirus related issues.

Please note that in this questionnaire, we do not intend to obtain data relating to identifiable persons.
Therefore, in case you will describe a particular experience or situation, please do it in a way that will not
allow linking to a particular individual, whether it is you or somebody else.

We thank you in advance for your time and input.

About you

• Language of my contribution
  ○ Bulgarian
  ○ Croatian
  ○ Czech
  ○ Danish
  ○ Dutch
  ○ English
  ○ Estonian
  ○ Finnish
  ○ French
  ○ Gaelic
  ○ German
  ○ Greek
  ○ Hungarian
  ○ Italian
  ○ Latvian
  ○ Lithuanian
  ○ Maltese
  ○ Polish
  ○ Portuguese
· I am giving my contribution as
  · Academic/research institution
  · Business association
  · Company/business organisation
  · Consumer organisation
  · EU citizen
  · Environmental organisation
  · Non-EU citizen
  · Non-governmental organisation (NGO)
  · Public authority
  · Trade union
  · Other

· Organisation name
  255 character(s) maximum
  European Heart Network (EHN)

· Organisation size
  · Micro (1 to 9 employees)
  · Small (10 to 49 employees)
  · Medium (50 to 249 employees)
  · Large (250 or more)

Transparency register number
  255 character(s) maximum
  Check if your organisation is on the transparency register. It's a voluntary database for organisations seeking to influence EU decision-making.
  3606882168-35

· Which stakeholder group do you represent?
Individual member of the public
Patient or consumer organisation
Healthcare professional
Healthcare provider organisation (incl. Hospitals, pharmacies)
Healthcare pricing & reimbursement body and/or final payer
Centralised health goods procurement body
Health technology assessment body
Academic researcher
Research funder
Learned society
European research infrastructure
Other scientific organisation
Environmental organisation
Pharmaceuticals industry
Chemicals industry
Pharmaceuticals traders/wholesalers
Medical devices industry
Public authority (e.g. national ministries of health)
EU regulatory partner / EU institution
Non-EU regulator / non-EU body
Other (please specify)

Are you responding on behalf of a Small or Medium Sized Enterprise?

☐ Yes
☐ No

* First name
Marilena

* Surname
Vrana

* Email (this won't be published)
mvrana@ehnheart.org
<table>
<thead>
<tr>
<th>Country of origin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Please add your country of origin, or that of your organisation.</td>
</tr>
<tr>
<td>Afghanistan</td>
</tr>
<tr>
<td>Djibouti</td>
</tr>
<tr>
<td>Libya</td>
</tr>
<tr>
<td>Saint Martin</td>
</tr>
<tr>
<td>Saint Pierre and Miquelon</td>
</tr>
<tr>
<td>Åland Islands</td>
</tr>
<tr>
<td>Dominica</td>
</tr>
<tr>
<td>Liechtenstein</td>
</tr>
<tr>
<td>Saint Vincent and the Grenadines</td>
</tr>
<tr>
<td>Albania</td>
</tr>
<tr>
<td>Dominican Republic</td>
</tr>
<tr>
<td>Lithuania</td>
</tr>
<tr>
<td>São Tomé and Príncipe</td>
</tr>
<tr>
<td>Algeria</td>
</tr>
<tr>
<td>Ecuador</td>
</tr>
<tr>
<td>Luxembourg</td>
</tr>
<tr>
<td>Saudi Arabia</td>
</tr>
<tr>
<td>American Samoa</td>
</tr>
<tr>
<td>Egypt</td>
</tr>
<tr>
<td>Macau</td>
</tr>
<tr>
<td>San Marino</td>
</tr>
<tr>
<td>Andorra</td>
</tr>
<tr>
<td>El Salvador</td>
</tr>
<tr>
<td>Madagascar</td>
</tr>
<tr>
<td>Seychelles</td>
</tr>
<tr>
<td>Angola</td>
</tr>
<tr>
<td>Equatorial Guinea</td>
</tr>
<tr>
<td>Malawi</td>
</tr>
<tr>
<td>Senegal</td>
</tr>
<tr>
<td>Anguilla</td>
</tr>
<tr>
<td>Eritrea</td>
</tr>
<tr>
<td>Malaysia</td>
</tr>
<tr>
<td>Senegal</td>
</tr>
<tr>
<td>Antarctica</td>
</tr>
<tr>
<td>Estonia</td>
</tr>
<tr>
<td>Maldives</td>
</tr>
<tr>
<td>Senegal</td>
</tr>
<tr>
<td>Antigua and Barbuda</td>
</tr>
<tr>
<td>Eswatini</td>
</tr>
<tr>
<td>Mali</td>
</tr>
<tr>
<td>Sierra Leone</td>
</tr>
<tr>
<td>Argentina</td>
</tr>
<tr>
<td>Ethiopia</td>
</tr>
<tr>
<td>Malta</td>
</tr>
<tr>
<td>Singapore</td>
</tr>
<tr>
<td>Armenia</td>
</tr>
<tr>
<td>Falkland Islands</td>
</tr>
<tr>
<td>Marshall Islands</td>
</tr>
<tr>
<td>Sint Maarten</td>
</tr>
<tr>
<td>Aruba</td>
</tr>
<tr>
<td>Faroe Islands</td>
</tr>
<tr>
<td>Martinique</td>
</tr>
<tr>
<td>Slovakia</td>
</tr>
<tr>
<td>Australia</td>
</tr>
<tr>
<td>Fiji</td>
</tr>
<tr>
<td>Mauritania</td>
</tr>
<tr>
<td>Slovenia</td>
</tr>
<tr>
<td>Austria</td>
</tr>
<tr>
<td>Finland</td>
</tr>
<tr>
<td>Mauritius</td>
</tr>
<tr>
<td>South Africa</td>
</tr>
<tr>
<td>Azerbaijan</td>
</tr>
<tr>
<td>France</td>
</tr>
<tr>
<td>Mayotte</td>
</tr>
<tr>
<td>South Africa</td>
</tr>
<tr>
<td>Bahamas</td>
</tr>
<tr>
<td>French Guiana</td>
</tr>
<tr>
<td>Mexico</td>
</tr>
<tr>
<td>South Georgia and the South Sandwich Islands</td>
</tr>
<tr>
<td>Bahrain</td>
</tr>
<tr>
<td>French Guiana</td>
</tr>
<tr>
<td>Micronesia</td>
</tr>
<tr>
<td>Somalia</td>
</tr>
<tr>
<td>Bangladesh</td>
</tr>
<tr>
<td>French Polynesia</td>
</tr>
<tr>
<td>South Africa</td>
</tr>
<tr>
<td>Barbados</td>
</tr>
<tr>
<td>French Southern and Antarctic Lands</td>
</tr>
<tr>
<td>South Korea</td>
</tr>
<tr>
<td>Belarus</td>
</tr>
<tr>
<td>Gabon</td>
</tr>
<tr>
<td>Monaco</td>
</tr>
<tr>
<td>South Sudan</td>
</tr>
<tr>
<td>Country/Region</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Central African Republic</td>
</tr>
<tr>
<td>Chad</td>
</tr>
<tr>
<td>Chile</td>
</tr>
<tr>
<td>China</td>
</tr>
<tr>
<td>Christmas Island</td>
</tr>
<tr>
<td>Clipperton</td>
</tr>
<tr>
<td>Cocos (Keeling) Islands</td>
</tr>
<tr>
<td>Colombia</td>
</tr>
<tr>
<td>Comoros</td>
</tr>
<tr>
<td>Congo</td>
</tr>
<tr>
<td>Cook Islands</td>
</tr>
<tr>
<td>Costa Rica</td>
</tr>
<tr>
<td>Côte d’Ivoire</td>
</tr>
<tr>
<td>Croatia</td>
</tr>
<tr>
<td>Cuba</td>
</tr>
<tr>
<td>Curaçao</td>
</tr>
<tr>
<td>Cyprus</td>
</tr>
<tr>
<td>Czechia</td>
</tr>
<tr>
<td>Democratic Republic of the Congo</td>
</tr>
<tr>
<td>Denmark</td>
</tr>
</tbody>
</table>

*Publication privacy settings*
The Commission will publish the responses to this public consultation. You can choose whether you would like your details to be made public or to remain anonymous.

- **Anonymous**
  Only your type of respondent, country of origin and contribution will be published. All other personal details (name, organisation name and size, transparency register number) will not be published.

- **Public**
  Your personal details (name, organisation name and size, transparency register number, country of origin) will be published with your contribution.

- I agree with the [personal data protection provisions](#)

---

### International dependency and manufacturing

*The EU is increasingly dependent on active ingredients originating from outside the EU. This has implications, including as regards increasing the risk of quality issues and shortages of medicines. The recent outbreak of COVID-19 shows that a disruption in the pharmaceutical products supply chain originating from outside the EU could present a major health security issue.*

1. **What type of EU action or initiative do you consider helpful to incentivise the production of active pharmaceutical ingredients for essential medicines (e.g. antibiotics, oncology medicines) in the EU?**

   *800 character(s) maximum*

   Encourage research and innovation for all essential medicines and increase transparency in the development of medicines. Establish a collaboration with patient organisations, academic and medical societies, and regulators to develop a common understanding on unmet need and develop a list of priority medicines for all EU patients, including the 60 million CVD patients living in the EU. Research is needed on models aimed at fostering the production of active pharmaceutical ingredients also within the EU in order not to rely heavily on APIs from outside the EU. EHN is prepared to provide the patients’ perspective for the large sector of CVD.

2. **What action do you consider most effective in enhancing the high quality of medicines in the EU?**

   *between 1 and 1 choices*

   - [ ] Stronger enforcement of the marketing authorisation holder responsibilities
   - [ ] Increased official controls in the manufacturing and distribution chain
   - [ ] Other (please specify)
   - [ ] I don’t know
Access to affordable medicines

A shortage of a medicine occurs when there are not enough medicines in a country to treat every patient with a given condition. Shortages can have a big impact on patients if their treatment is delayed because there is no alternative, or the alternative is not suited to their needs.

3. Are you concerned about medicines shortages in the EU?
   ○ I am concerned
   ○ I am not concerned
   ○ I have no particular opinion

If you wish, please elaborate your reply.

500 character(s) maximum

Medicine shortages is a systemic problem with diverse root causes. Shortages of cardiovascular medicines have become increasingly common. Surveys by the European Association of Hospital Pharmacists show a worrying upward trend of CVD shortages (https://bit.ly/32xhP12). Given few therapeutic alternatives to drugs in short supply, these shortages pose a major challenge and have heavy consequences on CVD patients’ health.

4. Which actions do you think would have the biggest impact on reducing shortages in the EU?

   at most 3 choice(s)

   ✓ Stronger obligations on medicines producers, and other players in the supply chain to ensure medicines are available
   □ Transparent information exchange among authorities on medicine stocks available in each country
   ✓ Increased cooperation among public authorities/national governments on shortages
   □ Multi-lingual packaging and electronic product information leaflets facilitating purchasing in different countries
   □ Providing incentives to companies to increase the production of medicines in the EU
   □ Inform on and make available to patients suitable substitutes for medicines that are at risk of shortage
   ✓ Other (please specify).

Please elaborate your reply.

500 character(s) maximum
Establish a collaboration with patient organisations, academic and medical societies, and regulators to co-develop a list of essential medicines for Europe and possible alternatives in case on shortages. Put in place a rigorous monitoring and forecast system for shortages. Improve communications and coordination with all stakeholders to prevent and mitigate shortages.

_Innovative medicines have to undergo a centralised EU-wide marketing authorisation. Companies often initially market them in a limited number of EU countries. It can take several years before patients in the other EU countries have access to those products._

5. Do you think that companies that apply for and receive an EU-wide marketing authorisation should be required to make that product available in all EU countries?
   - I agree
   - I neither agree or disagree
   - I disagree
   - I don't know

_If you wish, please elaborate your reply._

_500 character(s) maximum_

Diversity of national mechanisms for pricing and reimbursement contribute to inequalities in access across the EU. National decisions on pricing and reimbursement can be informed by an EU HTA process. A positive outcome of the EU HTA Regulation proposal together with increased transparency and coordination between EU countries could help improving unequal availability.

_In recent years, there has been an increase in the number of medicines withdrawn from the market upon decisions by the manufacturers._

6. Do you have an opinion on the reasons for these market withdrawals?
   - Yes
   - No

_If yes, please elaborate._

_500 character(s) maximum_

Recently, several pharmaceutical companies moved out of the cardiovascular field. Lengthy and costly CTs combined with payers prioritising innovation in areas of unmet need (two concepts needing urgently a common understanding by all stakeholders) and their reluctance to reimburse therapies that produce incremental effects are reasons for such disinvestment. For a sustainable pharma strategy, views of patients on (CVD) innovation and value assessment must be central to decision-making.
7. Are you aware of patients not receiving the medicine they need because of its price?

- Yes
- No

If you wish, please elaborate your reply.

500 character(s) maximum

Pricing and affordability rely on diverse national reimbursement systems. Setting prices is complex and need to factor in many variables including, costs (R&D, manufacturing etc), market needs, size, added therapeutic value for patients and a reasonable profit. Legislation currently in place can be used different than intended with negative consequences to access due to higher prices. Increased EU cooperation may contribute to achieving more equitable access.

8. Do you think that medicine prices are justified, taking into consideration the costs associated to their development and manufacturing?

- Yes
- No
- I don't know

If you wish, please elaborate your reply.

500 character(s) maximum

Diversity of national mechanisms to set prices contribute to inequalities in access across the EU. Medicine prices must justify costs and proved added value for patient-relevant outcomes. Transparency on costs and greater EU collaboration are means to enhance affordability and reduce inequalities of access across the EU. The WHO fair pricing initiative must be considered and an open multi-stakeholder dialogue on fairness and reasonable profit shall be supported.

High prices for new medicines put pressure on public health spending. The costs for research and development are not publically disclosed and there is no agreement on how to calculate such costs. In certain cases, some EU countries join forces to increase their negotiating power when discussing prices with pharmaceutical companies. Individual pricing decisions in some EU countries may affect others. As an example, some EU countries limit the prices of medicines by linking that price to average prices in other EU countries (we call this "external reference pricing"- ERP). Because of ERP, a pricing decision in one EU country can inadvertently affect the prices in others. Once patents and other forms of market protection expire, generic and biosimilar medicines can enter the market and compete with the existing ones, this also typically brings down prices. Finally, there are plans to strengthen support to EU countries to work with each other on the clinical effectiveness of new medicines compared to existing alternatives, simply put how much better a medicine works compared to another one. This is part of the so called “health technology assessment” process.

9. What are the most effective ways the EU can help improve affordability of medicines for health systems?
Support the EU countries in better assessing and/or evaluating the value of medicines, meaning the effectiveness of a (new) medicine compared with existing ones

Help EU countries share experiences and pool expertise on pricing and procurement methods

Better coordination among EU countries to ensure that pricing decisions taken by one EU country do not lead to negative impacts on patient access in another EU country

Facilitate, market entry and a healthy market functioning for generics and biosimilars

More transparency on how the cost of a medicine relates to the cost of its research and development

There should be a fair return on public investment when public funds were used to support the research and development of medicines

I don't know

Other

Innovation in early development and authorisation

The European Commission actively supports health research and development through various funding mechanisms (e.g. Multiannual Financial Framework, Horizon 2020, Innovative Medicines Initiative partnership) and through collaborations between academia, healthcare systems and industry. Furthermore, the EU pharmaceutical legislation includes incentives to stimulate the development of innovative new medicines in areas such as paediatric and rare diseases; and market exclusivity rights to industry.

10. What actions at EU level do you consider most effective in supporting innovative research and development of medicines? 

Make the legislative framework more adaptive to new technologies and advances in science

Provide more public funding for research

Support (including through funding) private-public partnerships

Support (including through funding) the creation of start-ups in medical research

Foster research collaboration between universities, research centres and industry


Provide research and development incentives in the form of intellectual property or market exclusivity rights for pharmaceutical companies investing in research

- Simplify the requirements for the conduct of clinical trials
- Other (please specify)
- I don't know

Please elaborate your reply.

100 character(s) maximum

Public investment in harmonised & interoperable CVD registries to improve speed & efficacy of CTs.

Expected return on investment in research and development for the pharmaceutical industry depends also on the expected volume of sales; this seems to be one of the root causes of limited availability of certain medicines (e.g. medicines for rare diseases or medicines for children).

11. What do you consider are the most effective actions related to research and development of medicines in areas where there are limited or no therapeutic options (unmet needs)?

at most 3 choice(s)

- Provide market protection (protect a new medicine from competition)
- Provide intellectual property protection
- Provide data protection (protection of the data related to a medicine’s clinical trials)
- Agree on a common understanding on what are the areas of unmet need in the EU
- Funding more targeted research at EU level
- Funding more targeted research at national level
- Provide national schemes to support companies economically
- I don’t know / no opinion
- Other (please specify)

The health sector is becoming more digitised, thanks to the increased availability and collection of health data from sources such as electronic health records, patient and disease registries and mobile apps (i.e. real world data) and through the use of artificial intelligence (AI) (i.e. systems that display intelligent behaviour and the use of complex algorithms and software in the analysis of complex health data). These developments, combined with real world data are transforming health, including the discovery of medicines.
12. Which **opportunities** do you see in digital technologies (such as artificial intelligence and use of real world data) for the development and use of medicines?

*600 character(s) maximum*

Digitalisation is steering medicine away from manual data entry and relatively basic statistical tools to a bottom-up data management that involves real-time data extraction and analysis of various sources, from electronic medical records, wearable devices, patient reported outcomes, registries and other. This offers the opportunity to improve the design, speed and efficacy of randomised controlled trials for the development of new CVD medicines at lower cost. A balanced regulatory approach weighing digital innovations against protection of personal data is needed. [https://bit.ly/33qANFI](https://bit.ly/33qANFI)

13. Which **risks** do you see in digital technologies (such as artificial intelligence and use of real world data) for the development and use of medicines?

*600 character(s) maximum*

To date, most healthcare innovations are mainly technology-driven. In the future, digital health R&I must be driven more by patients’ needs. Interoperability, data standards and quality controls are key to foster reliability and trustworthiness to digital technologies and AI algorithms. Scientific validation of technological innovation is important but it is difficult to follow the speed of technological developments. A uniform legal framework on the use digital technologies in healthcare is important to monitor and assess the quality of digital innovation while ensuring GDPR compliance.

Continuous manufacturing, advanced process analytics and control, 3D printing and portable/modular systems, may revolutionise the way medicines are manufactured.

14. Are you aware of any obstacles in the EU in taking advantage of technological progress in the manufacturing of medicines?

- [ ] Yes
- [ ] No
- [ ] I don’t know

If yes, could you please specify.

*500 character(s) maximum*

Obstacles in the EU for taking advantage of technological progress in the manufacturing of medicines is also the economic climate which makes it more difficult to foresee long-time planning or bold investments in new manufacture practices.

*Clinical trials* are investigations in humans to discover if a new medicine is safe and effective. Clinical trials can also be used to test if a new treatment is more effective and/or safer than the standard treatment. Finally, so called “pragmatic clinical trials” can be conducted to compare the safety and effectiveness of different standard treatments in real world setting.
15. How could clinical trials in the EU be driven more by patients’ needs while keeping them robust, relevant and safe for participants?

**at most 3 choice(s)**

- By providing more national support for the conduct of so-called “pragmatic trials” with the aim to optimise treatment to patients
- By better coordination for larger trials comparing different treatment strategies (covering medicines and other treatments such as surgery, radiotherapy, physiotherapy)
- By providing support for non-commercial organisations to conduct clinical trials in fields where financial interest is weaker
- By involving patients’ experiences in early phases of medicine design (e.g. factor-in how the disease affects their lives and develop medicines to target symptoms that are particularly important to patients)
- By designing more trials that collect information on medicine tolerability or the impact of a treatment on the quality of life
- By taking into consideration during the design of a trial the burden of trial participation on patients’ life
- Other (please specify).

Please elaborate your reply.

*100 character(s) maximum*

Patients’ real needs are key to factor-in from the outset to ensure value, efficacy and adherence.

Certain medicines are developed based on genes, cells or tissue engineering. Some of these products are developed in hospitals. These are covered by the notion of advanced therapy medicines.

16. Is the current legal framework suitable to support the development of cell-based advanced therapy medicines in hospitals?

- I strongly agree
- I partially agree
- I disagree
- I don’t know

Environmental sustainability of medicines and health challenges
Residues of several medicines have been found in surface and ground waters, soils and animal tissues across the Union. As of yet, no clear link has been established between medicine residues present in the environment and direct impacts on human health. However, the issue cannot be ignored and there is a need for a precautionary approach.

17. What actions at EU level do you consider most effective in limiting the negative environmental impact of medicines?

- Cleaner manufacturing processes
- Enhanced application of the polluter pays principle
- Review the way the Environment Risk Assessment of a medicine is conducted and its consequences on the authorisation process
- Clear labelling of environmental risks to allow informed choices among equivalent therapeutic options
- Reference to environmental risks in advertising for over-the-counter medicines
- Make medicines known to pose an environmental risk available by prescription only
- Strict disposal rules for unused medicines
- Prescribe medicines only when it is absolutely necessary (more prudent use)
- Medicines dispensed to patients in the quantity actually needed (e.g. number of pills, volume of solution)
- Enhanced wastewater treatment if certain residues could be better removed
- Other (please specify)

Antimicrobial resistance (AMR) is the ability of microorganisms (such as bacteria, viruses, fungi or parasites) to survive and grow in the presence of medicines. It reduces progressively the effectiveness of antimicrobials and is caused, among other things, by extensive and improper use of antimicrobial medicines. Antimicrobials include antibiotics, which are substances that fight bacterial infections. AMR can lead to problems such as difficulties to control infections, prolonged hospital stays, increased economic and social costs, and higher risk of disease spreading. AMR is one of the most serious and urgent public health concerns.

18. Which actions do you think would have the biggest impact on fighting AMR concerning the use of medicines for patients?

- More prudent use of antimicrobials (if necessary through restrictions on prescriptions)
Improve the treatment of wastewater and/or manure to lower the levels of antimicrobials

- Raise citizens’ and healthcare practitioners’ awareness by informing them on appropriate use of antimicrobials and the correct disposal of unused medicines
- Introduce an obligation to use diagnostic tests before prescribing antimicrobials, for example to verify whether it is a bacterial infection before prescribing antibiotics and to define the most adequate antibiotic
- Public finance research and innovation on new antimicrobials, their alternatives and diagnostics
- Encourage public health campaigns that prevent infection through better general health including increased immunity
- Encourage public health campaigns that prevent infection through the use of vaccines
- Encourage better hygiene measures in hospitals
- Other (please specify)
- I don’t know

_Innovation in antimicrobials is limited. For example, no new classes of antibiotics have been discovered for decades. Restricting the use of antibiotics to minimise the risk of developing resistance is a commercial disincentive for investment, as potential investors are concerned that their investment will not be profitable._

19. Where, in your view, should the EU focus its support for the creation of new antimicrobials or their alternatives?

at most 2 choice(s)

- Support academia for researching/discovering new antimicrobials or their alternatives
- Support industry for developing new antimicrobials or their alternatives
- Provide specific support to small and medium-sized enterprises (SMEs)
- Other (please specify)
- I don’t know

Please elaborate your reply.

100 character(s) maximum

_New research & innovation models should be explored._
Health threats such as the coronavirus disease test the limits of public health systems, the pharmaceutical industry and of the pharmaceutical legislation. From the beginning of the coronavirus (COVID-19) pandemic, the EU has taken measures to coordinate a response, which includes actions ensuring the availability of medicines.

20. How has the coronavirus (COVID-19) pandemic affected you in relation to access to medicines and treatments?

600 character(s) maximum

The continuity of treatment for patients who could not or no longer wanted to go to hospital due to COVID-19 was seriously disrupted. Many EU countries reported significant declines of the number of heart attack and stroke patients seeking emergency care due to fears of infection or overloaded ambulance and emergency services. Re-prioritisation of hospital resources decreased significantly access to cardiovascular services with a drastic reduction of cardiac surgery. Delays in the delivery of different interventions have compromised CVD patients’ safety and the efficacy of their treatment.

21. In your opinion and based on your experience, what can the EU do to prepare for and manage such a situation better in the future in relation to pharmaceuticals?

600 character(s) maximum

The pandemic is calling for a flexible system for rapid and efficient clinical trials without jeopardising patients’ safety. Establish a structured collaboration between academic clinical trialists, patients, regulators and industry to modernise the International Council of Harmonisation (ICH) Good Clinical Practice (GCP) standards and make them fit for the digital era.
Secure a positive outcome for the EU legislative proposal on Health Technology Assessment, covering the assessment of both medicines and medical devices.

Summary question

22. While the Commission is working on improving the EU pharmaceuticals framework, which areas of work do you find most urgent?

at most 3 choice(s)

- [x] Improve patients’ access to medicines
- [ ] Reduce shortages
- [ ] Help national authorities ensure affordability for patients and increase health systems sustainability
- [x] Support innovation for unmet needs
- [ ] Use of digitalisation to develop medicines
- [ ] Help reduce anti-microbial resistance
- [ ] Reduce the dependency on essential active ingredients and medicines produced outside the EU
- [ ]
Environmental sustainability of medicines

☐ I don’t know

☑ Other (please specify)

Please elaborate your reply.

100 character(s) maximum

A common understanding is needed on concepts of innovation, unmet need and added therapeutic value.

23. If you were asked before the coronavirus (COVID-19) pandemic, would you have responded differently to any of the previous questions?

☐ Yes

☐ No

☐ I don’t know

24. Is there anything else you would like to add that has not been covered in this consultation?

900 character(s) maximum

The burden of cardiovascular disease is greater than that of any other disease & the leading cause of death in the EU. Yet investments in CVD R&I are lagging behind despite the need and the large potential for discovery and innovation. The complexity and costs of CTs, disproportionately low funding for CVD research & an unfavourable regulatory framework are key contributors to the lack of CVD innovation. Access, shortages and affordability are multifaceted challenges. Innovation & unmet need lack common understanding from all stakeholders. The EU pharmaceutical strategy should address these challenges. Areas for action should include improving the regulatory framework to modernise CTs fit for the digital era while ensuring safety, efficacy and data protection; securing a positive outcome on the proposed EU HTA Regulation, covering both medicines and medical devices. https://bit.ly/2FuRB

You may upload a position paper here.

The maximum file size is 1 MB

Only files of the type pdf, txt, doc, docx, odt, rtf are allowed

Contact
EU-PHARMACEUTICAL-STRATEGY@EC.EUROPA.EU